The vaccine against cancer is the hope of many people. Thus, after the “wondrous formula”, which can remove the tumors, was announced, the researchers tested the cancer vaccine on mice. The result is more than satisfactory.
The study conducted by researchers at Stanford University School of Medicine shows that injecting two immunostimulating agents in small amounts directly into the solid tumors of mice can eliminate all traces of cancer. This vaccine could be the most important medical discovery for mankind.
The method works for many different types of cancer, even in case of spontaneous tumors. Researchers believe that local application of very small amounts of these agents could serve as a quick and relatively cheap therapy in the fight against tumors. In addition, the chances of having side effects after applying this kind of therapy are very low.
This vaccine avoids the need to identify tumor-specific immunity targets and does not require the significant activation of the immune system, or to personalize the immune cells of the patient. One of the two agents is already approved for use in humans, while the other has been tested for human use in several independent clinical trials. A clinical trial was launched in January and tested the effect of treatment in patients with lymphoma.
Ronald Levy, a professor of oncology, is a pioneer in cancer immunotherapy, a field where researchers are trying to harness the immune system to fight cancer. Research in his laboratory has led to the development of Rituximab, one of the first monoclonal antibodies approved for use as an anticancer treatment in humans. He is the one who led the study that can change and save many lives.
“When we use these two agents together, we see the elimination of tumors all over the body,” Dr. Levy stated.
The testing involved 90 mice suffering from cancer. The cancer vaccine was injected in all of them but cured only 87 mice out of the 90. The odds look good and the researchers are looking forward to implementing the cancer vaccine in humans.